Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxel

Acta Oncologica

Volumn 43, Issue 2, 2004, Pages 190-195

  Poikonen, Paula ^a   Sjöström, Johanna ^a   Klaar, Sigrid ^b   Nittby, Lena Tennvall ^c   Sigurdsson, Helgi ^d   Madsen, Ebbe Lindegaard ^e   Joensuu, Heikki ^a   Blomqvist, Carl ^f  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^e Klinisk Mikrobiologisk Afdeling   (Denmark)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; HEMOGLOBIN;

ADULT; AGED; ARTICLE; ASSOCIATION; BLOOD CELL COUNT; BLOOD DISEASE; BLOOD TOXICITY; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; LEUKOCYTE; LEUKOPENIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; METASTASIS; MOUTH DISEASE; MOUTH INFECTION; MOUTH MUCOSA; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NAUSEA; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SKIN TOXICITY; STATISTICAL SIGNIFICANCE; STOMATITIS; TOXICITY; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III; FEMALE; HUMANS; INFECTION; LEUKOCYTE COUNT; MIDDLE AGED; MOUTH MUCOSA; MUCOUS MEMBRANE; NEUTROPENIA; REGRESSION ANALYSIS; SKIN; TAXOIDS;

EID: 11144353697     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860310022977     Document Type: Article

References (19)

1. Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995; 13: 314-22.
2. Ravdin PM, Burris H, III, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995; 13: 2879-85.
3. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13: 2886-94.
4. Hudis CA, Seidman AD, Crown JP, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 58-65.
5. Trudeau ME, Eisenhauer EA, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996; 14: 422-8.
6. Fumoleau P, Chevallier B, Kerbrat P, et al. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol 1996; 7: 165-71.
7. Salminen E, Bergman M, Huhtala S, et al. Docetaxel: standard recommended dose of 100 mg/m2 is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy - a phase II single-center study. J Clin Oncol 1999; 17: 1127-31.
8. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 1999; 17: 2341-54.
9. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999; 17: 1413-24.
10. Sjostrom J, Blomqvist C, Mouridsen H, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999; 35: 1194-201.
11. Ozer H, Armitage JO, Bennett CL, et al. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence based, clinical practice guidelines. J Clin Oncol 2000; 18: 3558-85.
12. Anonymous. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994; 12: 2471-508.
13. Bodey GP. Infection in cancer patients. A continuing association. Am J Med 1986; 81: 11-26.
14. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16: 187-96.
15. Sonis ST, Sonis AL, Lieberman A. Oral complications in patients receiving treatment for malignancies other than of the head and neck. J Am Dent Assoc 1978; 97: 468-72.
16. Schimpff SC, Gaya H, Klastersky J, et al. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group. J Inf Dis 1978; 137: 14-29.
17. Heimdahl A, Mattsson T, Dahllof G, et al. The oral cavity as a port of entry for early infections in patients treated with bone marrow transplantation. Oral Surg Oral Med Oral Pathol 1989; 68: 711-6.
18. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995; 13: 2643-55.
19. Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-40.